

In re Appln. of Chamberlain et al.
Application No. 09/838,987

D1
Ch

immunogen, 10^7 PFU of rVV expressing β -gal (VJS6), 10^7 PFU of rFPV expressing β -gal (rFPV) or $10\mu\text{g}$ of pCMV/ β -gal (DNA). **Fig. 1B** – data of mice primed with VJS6 and later boosted by either no immunogen, VJS6, rFPV or DNA. **Fig. 1C** – data of mice primed with rFPV and later boosted by either no immunogen, VJS6, rFPV or DNA. **Fig. 1D** – data of mice primed with DNA and later boosted by either no immunogen, VJS6, rFPV or DNA. **Fig. 1E** – data of mice primed with no immunogen, VJS6, rFPV or DNA and then boosted with DNA. The no treatment group (None – None) is shown in all graphs of **Fig. 1** as a control group.

IN THE CLAIMS:

Please cancel claims 9-20 without prejudice to reinstate.

Please amend claims 1-8 to read as follows:

1. (Thrice Amended) A method for inducing an immune response against at least one in a mammal, which method comprises:

D2

- (i) inoculating the mammal with a first recombinant vector comprising a nucleic acid insert encoding at least one antigen against which an immune response is to be induced; and
- (ii) inoculating the mammal with a second recombinant vector comprising a nucleic acid insert encoding at least one antigen against which an immune response is to be induced, wherein the second DNA vector is different from the first DNA vector and wherein at least one antigen encoded by the insert of the first recombinant vector is encoded by the insert of the second recombinant vector, whereupon an immune response against at least one antigen is induced in the mammal.

2. (Twice Amended) The method according to claim 1, wherein the first recombinant vector is a recombinant vaccinia viral vector.

3. (Twice Amended) The method according to claim 1, wherein the first recombinant vector is a recombinant fowlpox viral vector.